Literature DB >> 9499112

Autocrine regulation and experimental modulation of interleukin-6 expression by human pulmonary epithelial cells infected with respiratory syncytial virus.

Z Jiang1, M Kunimoto, J A Patel.   

Abstract

The mechanisms of regulation of interleukin-6 (IL-6) production in respiratory syncytial virus (RSV)-infected respiratory epithelial cells were evaluated in A549 cell cultures. Incubation with purified RSV resulted in significant production of IL-1alpha, IL-1beta, IL-6, and tumor necrosis factor alpha (TNF-alpha). Addition of saturating concentrations of neutralizing antibodies against IL-1alpha, IL-1beta, or TNF-alpha into purified RSV-infected cell cultures resulted in a significant inhibition of IL-6 production, although anti-IL-1alpha antibody had the most predominant effect (80% inhibition). Anti-IL-1alpha antibody also almost completely blocked the expression of mRNA for IL-6. Addition of therapeutic concentrations of dexamethasone (1 microM) or ribavirin (90 microg/ml), an antiviral agent, also significantly inhibited the synthesis of IL-6. Hence, in clinical settings, pharmacological agents such as the specific antagonists of IL-6-inducing cytokines, as well as dexamethasone and ribavirin, could be used to modulate IL-6 production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499112      PMCID: PMC109551          DOI: 10.1128/JVI.72.3.2496-2499.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion.

Authors:  A Ray; K S LaForge; P B Sehgal
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life.

Authors:  C J Holberg; A L Wright; F D Martinez; C G Ray; L M Taussig; M D Lebowitz
Journal:  Am J Epidemiol       Date:  1991-06-01       Impact factor: 4.897

Review 3.  Interleukin-6: a comprehensive review.

Authors:  M Lotz
Journal:  Cancer Treat Res       Date:  1995

Review 4.  Interleukin-6: an overview.

Authors:  J Van Snick
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

Review 5.  Asthma pharmacotherapy: current practices and outlook.

Authors:  H W Kelly
Journal:  Pharmacotherapy       Date:  1997 Jan-Feb       Impact factor: 4.705

6.  Induction of IL-6 (B cell stimulatory factor-2/IFN-beta 2) production by HIV.

Authors:  K Nakajima; O Martínez-Maza; T Hirano; E C Breen; P G Nishanian; J F Salazar-Gonzalez; J L Fahey; T Kishimoto
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

7.  Identification of an interleukin HP1-like plasmacytoma growth factor produced by L cells in response to viral infection.

Authors:  S Cayphas; J Van Damme; A Vink; R J Simpson; A Billiau; J Van Snick
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

8.  Interleukin-1 alpha mediates the enhanced expression of intercellular adhesion molecule-1 in pulmonary epithelial cells infected with respiratory syncytial virus.

Authors:  J A Patel; M Kunimoto; T C Sim; R Garofalo; T Eliott; S Baron; O Ruuskanen; T Chonmaitree; P L Ogra; F Schmalstieg
Journal:  Am J Respir Cell Mol Biol       Date:  1995-11       Impact factor: 6.914

9.  Effects of ribavirin on respiratory syncytial virus in vitro.

Authors:  J F Hruska; J M Bernstein; R G Douglas; C B Hall
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

10.  Regulation of the acute phase and immune responses in viral disease. Enhanced expression of the beta 2-interferon/hepatocyte-stimulating factor/interleukin 6 gene in virus-infected human fibroblasts.

Authors:  P B Sehgal; D C Helfgott; U Santhanam; S B Tatter; R H Clarick; J Ghrayeb; L T May
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  16 in total

1.  The respiratory syncytial virus (RSV) nonstructural proteins mediate RSV suppression of glucocorticoid receptor transactivation.

Authors:  Jeanette I Webster Marketon; Jacqueline Corry; Michael N Teng
Journal:  Virology       Date:  2013-11-26       Impact factor: 3.616

2.  Resveratrol Inhibits respiratory syncytial virus-induced IL-6 production, decreases viral replication, and downregulates TRIF expression in airway epithelial cells.

Authors:  Xiao-Hong Xie; Na Zang; Si-min Li; Li-jia Wang; Yu Deng; Yun He; Xi-qiang Yang; En-mei Liu
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

3.  Modulation of respiratory syncytial virus-induced prostaglandin E2 production by n-3 long-chain polyunsaturated fatty acids in human respiratory epithelium.

Authors:  Dani-Louise Bryan; Prue Hart; Kevin Forsyth; Robert Gibson
Journal:  Lipids       Date:  2005-10       Impact factor: 1.880

4.  Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells.

Authors:  Yuhong Zhang; Mohammad Jamaluddin; Shaofei Wang; Bing Tian; Roberto P Garofalo; Antonella Casola; Allan R Brasier
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow.

Authors:  Kimberly D Dyer; Jennifer M Moser; Meggan Czapiga; Steven J Siegel; Caroline M Percopo; Helene F Rosenberg
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 6.  Activation of Proinflammatory Responses in Cells of the Airway Mucosa by Particulate Matter: Oxidant- and Non-Oxidant-Mediated Triggering Mechanisms.

Authors:  Johan Øvrevik; Magne Refsnes; Marit Låg; Jørn A Holme; Per E Schwarze
Journal:  Biomolecules       Date:  2015-07-02

7.  A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.

Authors:  Craig W Day; Ralph Baric; Sui Xiong Cai; Matt Frieman; Yohichi Kumaki; John D Morrey; Donald F Smee; Dale L Barnard
Journal:  Virology       Date:  2009-10-22       Impact factor: 3.616

8.  Anticancer oncolytic activity of respiratory syncytial virus.

Authors:  I Echchgadda; S Kota; I DeLa Cruz; A Sabbah; T Chang; R Harnack; V Mgbemena; B Chatterjee; S Bose
Journal:  Cancer Gene Ther       Date:  2009-05-15       Impact factor: 5.987

9.  Induction of IL-6 and CCL5 (RANTES) in human respiratory epithelial (A549) cells by clinical isolates of respiratory syncytial virus is strain specific.

Authors:  Ruth Levitz; Rachel Wattier; Pamela Phillips; Alexandra Solomon; Jessica Lawler; Isaac Lazar; Carla Weibel; Jeffrey S Kahn
Journal:  Virol J       Date:  2012-09-10       Impact factor: 4.099

10.  Respiratory syncytial virus induced type I IFN production by pDC is regulated by RSV-infected airway epithelial cells, RSV-exposed monocytes and virus specific antibodies.

Authors:  Marcel A Schijf; Michael V Lukens; Debby Kruijsen; Nathalie O P van Uden; Johan Garssen; Frank E J Coenjaerts; Belinda Van't Land; Grada M van Bleek
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.